Forest/Almirall's COPD drug set for mid-year filing on positive Phase III
This article was originally published in Scrip
Forest Laboratories and Almirall's chronic obstructive pulmonary disease (COPD) therapy has met the primary endpoints in its third Phase III trial, say the companies. Regulatory submissions in both Europe and the US for aclidinium bromide monotherapy are planned for mid 2011.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.